A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood

This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. The trial is a six-week, single-arm, open-label, virtual study enrolling 30 participants.

Participants will consume test product one (2.5 oz once daily) during Weeks 1 and 2, undergo a washout period during Weeks 3 and 4, and then consume test product two (2.5 oz once daily) during Weeks 5 and 6. Cognitive function will be assessed via standardized computerized cognitive assessments at Baseline, Week 2, Week 4, and Week 6, while perceptions of cognitive function, cognitive performance, and mood will be captured through self-reported questionnaires at Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6.

Study Overview

• Status: Completed
• Conditions: Cognitive Function; Mood; Cognitive Performance
• Intervention / Treatment: Dietary supplement: BrainJuice Supplement

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89101
      • Citruslabs

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Be male or female
• Be aged 18-57
• Anyone experiencing concerns regarding all of the following over the past four weeks: Cognitive Function, Cognitive Performance, and Mood
• Anyone who is generally healthy - does not live with any uncontrolled chronic disease
• If taking oral over-the-counter supplements or herbal remedies targeted at cognitive function, cognitive performance, or mood, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration
• Anyone who is a regular caffeine consumer without a history of caffeine sensitivity or intolerance
• Willing to maintain the same diet and exercise regimen consistently throughout the study duration
• Willing to limit caffeine consumption to one additional serving of caffeine outside of the test product i.e. one cup of brewed coffee (~100 mg), one matcha (~60 mg), two shots of espresso (~120 mg), or one cup of caffeinated tea (~50 mg)
• Resides in the United States
• Has access to a computer or tablet device

Exclusion Criteria:

• Anyone with pre-existing chronic conditions, including but not limited to oncological, uncontrolled hypertension (high blood pressure) or hypotension (low blood pressure), heart disease, diabetes and psychiatric disorders
• History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine
• History of mood disorders, such as depression, bipolar disorder, or seasonal affective disorder
• History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea
• Anyone with a job that involves shift work that may be overnight or night hours
• Planning on introducing any products or any new forms of prescription medication or supplements that target cognitive function, cognitive performance, or mood, for the study duration
• Anyone with any allergies or sensitivities to any of the study product ingredients
• Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
• Anyone unwilling to follow the study protocol
• Anyone with a history of substance abuse
• Anyone who is currently a smoker or has been a smoker in the past 3 months
• Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BrainJuice Supplement	Dietary supplement: BrainJuice Supplement; All participants consume BrainJuice Peach Mango (test product one, 2.5 oz once daily) during Weeks 1 and 2, followed by a washout period during Weeks 3 and 4 with no test product, followed by BrainJuice ACTIVE Pomegranate Acai (test product two, 2.5 oz once daily) during Weeks 5 and 6. There is no comparator or placebo arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Cognitive Assessment Score (Polygons)	Mean change in Polygons processing test score from Baseline, measured via computerized cognitive assessment	Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Double Trouble)	Mean change in Double Trouble selective attention and processing speed test score from Baseline, measured via computerized cognitive assessment	Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Feature Match)	Mean change in Feature Match focus and processing test score from Baseline, measured via computerized cognitive assessment	Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Paired Associates)	Mean change in Paired Associates memory task score from Baseline, measured via computerized cognitive assessment	Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Digit Span)	Mean change in Digit Span short-term memory and attention test score from Baseline, measured via computerized cognitive assessment	Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Spatial Planning)	Mean change in Spatial Planning executive function test score from Baseline, measured via computerized cognitive assessment	Baseline, Week 2, Week 4, and Week 6

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Self-Reported Focus	Mean change in perceived focus from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Attention	Mean change in perceived attention from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Concentration	Mean change in perceived concentration from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Productivity	Mean change in perceived productivity from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Alertness	Mean change in perceived alertness from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Clarity	Mean change in perceived mental clarity from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mood	Mean change in perceived mood from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Fatigue	Mean change in perceived mental fatigue from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Motivation	Mean change in perceived motivation from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Organization	Mean change in perceived organization from Baseline, assessed via self-reported questionnaire	Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6

Collaborators and Investigators

• Sponsor: BrainJuice
• Collaborators: Citruslabs

Study record dates

Study Major Dates

• Study Start (Actual): November 9, 2025
• Primary Completion (Actual): February 6, 2026
• Study Completion (Actual): February 6, 2026

Study Registration Dates

• First Submitted: August 11, 2026
• First Submitted That Met QC Criteria: August 11, 2026
• First Posted (Actual): August 14, 2026

Study Record Updates

• Last Update Posted (Actual): August 14, 2026
• Last Update Submitted That Met QC Criteria: August 11, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: 20807 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium); legacy-20807

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No